Trial Profile
Phase 1b/Phase 3 Multicenter Study Of Avelumab (msb0010718c) In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, Cd20 Antagonist And/or Conventional Chemotherapy In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (Dlbcl) Javelin Dlbcl
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Azacitidine (Primary) ; Bendamustine (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary) ; Utomilumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms JAVELIN DLBCL
- Sponsors Pfizer
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 20 Nov 2020 Status changed from completed to discontinued.
- 13 Sep 2020 This trial has been discontinued in Czech Republic , according to European Clinical Trials Database.